Strides Arcolab on Wednesday said it has received approval from the US health regulator to market its generic Doxorubicin Hydrochloride injection, used for treating cancer, in the American market.
Onco Therapies, a wholly-owned subsidiary of the company has received approval from the United States Food and Drug Administration (USFDA) for Doxorubicin Hydrochloride injection, Strides Arcolab said in a statement.
The approval has been given for the injection in the strengths of 10 mg/ vial and 50 mg/ vial, it added.
“Doxorubicin is part of the oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly,” Strides Arcolab said.
According to IMS data of June 2011, the US market for generic Doxorubicin is nearly $16.8 million. Doxorubicin is a cancer chemotherapy drug, commonly used in the treatment of a wide range of cancers and is administered intravenously, it added.
Shares of Strides Arcolab today closed at Rs 390.35 on BSE, down 3.15 per cent from its previous close.